Page 127 - 2019年2月第30卷第4期

Psoriasis prevalence among adults in the United States[J]. [15] TORRES T，ROMANELLI M，CHIRICOZZI A. A revolu-
J Am Acad Dermatol，2014，70（3）：512-516. tionary therapeutic approach for psoriasis：bispecific bio-
[ 2 ] 丁晓岚，王婷琳，沈佚葳，等.中国六省市银屑病流行病学 logical agents[J]. Expert Opin Investig Drugs，2016，25
调查[J].中国皮肤性病学杂志，2010，24（7）：598-601. （7）：751-754.
[ 3 ] MITRA A，FALLEN RS，LIMA HC. Cytokine-based ther- [16] MEASE P. Update on treatment of psoriatic arthritis[J].
apy in psoriasis[J]. Clinic Rev Allerg Immunol，2013，44 Bull NYU Hosp Joint Dis，2012，70（3）：167-171.
（2）：173-182. [17] LANGLEY RG，ELEWSKI BE，LEBWOHL M，et al.
[ 4 ] MANSOURI Y，GOLDENBERG G. Biologic safety in Secukinumab in plaque psoriasis-results of two phase 3 tri-
psoriasis：review of long-term safety data[J]. J Clin Aes- als[J]. N Engl J Med，2014，371（4）：326-338.
thet Dermatol，2015，8（2）：30-42. [18] GORDON KB，COLOMBEI JF，HARDIN DS，et al. Phase
[ 5 ] SHALOM G，ZISMAN D，BITTERMAN H，et al. System- 3 trials of ixekizumab in moderate-to-severe plaque psoria-
ic therapy for psoriasis and the risk of herpes zoster：a sis[J]. N Engl J Med，2016. DOI：10.1056/NEJMc1610828.
TM
500 000 person-year study[J]. JAMA Dermatol，2015，151 [19] FDA. SILIQ （brodalumab）injection[EB/OL].[2018-08-
（5）：533-538. 26].https：//www.accessdata.fda.gov/drugsatfda_docs/label/
[ 6 ] CHIU YM，TANG CH，HUNG ST，et al. A real-world risk 2017/761032lbl.pdf .
analysis of biological treatment（adalimumab and etaner- [20] TAUSEND W，DOWNING C，TYRING S. Systematic re-
cept）in a country with a high prevalence of tuberculosis view of interleukin-12，interleukin-17，and interleukin-23
and chronic liver disease：a nationwide population-based pathway inhibitors for the treatment of moderate-to-severe
study[J]. Scand J Rheumatol，2017，46（3）：236-240. chronic plaque psoriasis：ustekinumab，briakinumab，til-
[ 7 ] FDA. Product approval information[EB/OL].[2018-11-09]. drakizumab，guselkumab，secukinumab，ixekizumab，and
https：//www.accessdata.fda.gov/drugsatfda_docs/appletter/ brodalumab[J]. J Cutan Med Surg，2014，18（3）：156-169.
1998/inflcen082498L.htm. [21] FDA. TREMFYA（guselkumab）injection[EB/OL].[2018-
[ 8 ] SFDA. Product approval information[EB/OL].[2018-11-09]. 08-26].https：//www.accessdata.fda.gov/drugsatfda_docs/
http：//qy1.sfda.gov.cn/datasearchcnda/face3/base.jsp? label/2017/761061s000lbl.pdf .
tableId=36&tableName=TABLE36&title=％E8％BF％9B％ [22] BLAUVELT A，PAPP KA，GRIFFITHS CE，et al. Effica-
E5％8F％A3％E8％8D％AF％E5％93％81&bcId=1529- cy and safety of guselkumab，an anti-interleukin-23 mono-
04858822343032639340277073. clonal antibody，compared with adalimumab for the con-
[ 9 ] FDA. REMICADET （infliximab）injection[EB/OL].[2018- tinuous treatment of patients with moderate to severe pso-
TM
11-06]. https：//www.accessdata.fda.gov/drugsatfda_docs/ riasis：results from the phase Ⅲ，double-blinded，placebo-
label/2017/761032lbl.pdf. and active comparator-controlled VOYAGE 1 trial[J].J
[10] SMOLEN JS，EMERY P. Infliximab：12 years of experi- Am Acad Dermatol，2017，76（3）：405-417.
ence[J]. Arthritis Res Ther，2011. DOI：10.1186/1478-6354- [23] RYAN C，LEONARDI CL，KRUEGER JG，et al. Associa-
13-S1-S2. tion between biologic therapies for chronic plaque psoria-
TM
[11] FDA. ENBREL （etanercept）injection [EB/OL].[2018-11- sis and cardiovascular events：a meta-analysis of random-
06].https：//www.accessdata.fda.gov/drugsatfda_docs/label/ ized controlled trials[J]. JAMA，2011，306（8）：864-871.
1998/etanimm110298lb.pdf. [24] SCHAFER PH，PARTON A，GANDHI AK，et al. Apremi-
[12] 韩凌，方栩，黄琼，等.注射用重组人Ⅱ型肿瘤坏死因子受 last，a cAMP phosphodiesterase-4 inhibitor，demonstrates
体-抗体融合蛋白治疗中、重度寻常性银屑病疗效观察 anti-inflammatory activity in vitro and in a model of psori-
[J].临床皮肤科杂志，2007，36（11）：730-732. asis[J]. Br J Pharmacol，2010，159（4）：842-855.
[13] FDA. Product approval information[EB/OL].[2018-11-09]. [25] SCHETT G，WOLLENHAUPT J，PAPP K，et al. Oral
https：//www.accessdata.fda.gov/drugsatfda_docs/appletter/ apremilast in the treatment of active psoriatic arthritis：re-
2002/adalabb123102L.htm. sults of a multicenter，randomized，double-blind，place-
[14] THAÇI D，BLAUVELT A，REICH K，et al. Secukinumab bo-controlled study[J]. Arthritis Rheum，2012，64（10）：
is superior to ustekinumab in clearing skin of subjects 3156-3167.
with moderate to severe plaque psoriasis：CLEAR，a ran- [26] PAPP KA，KAUFMANN R，THAÇI D，et al. Efficacy and
domized controlled trial[J]. J Am Acad Dermatol，2015，73 safety of apremilast in subjects with moderate to severe
（3）：400-409. plaque psoriasis：results from a phase Ⅱ，multicenter，ran-

·546 · China Pharmacy 2019 Vol. 30 No. 4 中国药房 2019年第30卷第4期